101166-73-8

Basic information

• Product Name: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)
• Synonyms: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI);2-METHYLPYRIDINE-3-ACETONITRILE;(2-Methylpyridin-3-yl)acetonitrile;2-Methyl-3-pyridineacetonitrile;(2-Methyl-3-pyridinyl)acetonitrile
• CAS NO: 101166-73-8
• Molecular Formula: C8H8N2
• Molecular Weight: 132.16252
• Product Categories: PYRIDINE;Aromatics, Heterocycles, Intermediates, Metabolites & Impurities
• Mol File: 101166-73-8.mol

Chemical Properties

• Boiling Point: 136-137℃ (10 Torr)
• Flash Point: 99.9±8.3℃
• Appearance: /
• Density: 1.056±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.5255 (589.3 nm 25℃)
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• PKA: 4.89±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(101166-73-8)
• EPA Substance Registry System: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(101166-73-8)

Safety Data

• Hazardous Substances Data: 101166-73-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridineacetonitrile,2-methyl-(6CI,9CI) is used as a key intermediate in the synthesis of pyridine analogues of vitamin B1. Its unique structure allows for the development of novel compounds with potential therapeutic applications, contributing to the advancement of drug discovery and medicinal chemistry.
Used in Chemical Synthesis:
As a versatile building block, 3-Pyridineacetonitrile,2-methyl-(6CI,9CI) is utilized in the preparation of a wide range of pyridine-based compounds. Its reactivity and functional groups enable various chemical reactions, facilitating the synthesis of complex organic molecules for research and industrial applications.

Upstream product

• 31805-47-7 (2-methyl-[3]pyridyl)-acetic acid amide 
• 1721-12-6 1-(2-methylpyridin-3-yl)ethanone 
• 1118-66-7 4-amino-3-penten-2-one 
• 143-33-9 sodium cyanide 
• 120277-68-1 2-methyl-3-(chloromethyl)pyridine 
• 773837-37-9 sodium cyanide 

Downstream Products

• 504404-51-7 2-(2-methyl-[3]pyridyl)-ethylamine 
• 856833-61-9 bis-[2-(2-methyl-[3]pyridyl)-ethyl]-amine 
• 1977-05-5 2-(2-methylpyridin-3-yl)ethanol 

Relevant articles and documents

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES

The object of the invention is to provide new compounds which can be used for the treatment of diseases, in particular cardiovascular and haematological diseases. The present invention describes compounds which act as specific HIF-prolyl-4-hydroxylase inhibitors and which, because of this specific in vivo action mechanism, induce HIF target genes, such as erythropoietin, and the thus produced biological processes, such as erythropoiesis, after parenteral or oral administration. The present invention relates to compounds having the general formula (I), in which A stands for CH or N, R1 stands for a substituent selected from the group formed by (C1-C6)-alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C1-C6)-alkoxy, amino, (C1-C6)-alkoxycarbonyl, hydroxycarbonyl and C(=O)-NH-R4; R2 stands for a substituent selected from the group formed by halogen, cyano, nitro, (C1-C6)-alkyl, trifluoromethyl, hydroxy, (C1-C6)-alkoxy, trifluoromethoxy, amino, hydroxycarbonyl and C(=O)-NH-R8; m equals 0, 1 or 2; n equals 0, 1, 2 or 3, it being possible for these meanings to be the same or different when R1 or R2 occurs multiple times; and R3 stands for hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl. The invention also relates to the salts, solvates, and salt solvates of these compounds.

Cyanoamidine P2X7 antagonists for the treatment of pain

Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.